PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower life science innovations.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer") to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offer Securities”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California.

On December 1, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (referred to as the “Company” or “Mindray”, SZSE: 300760) announced the completion of its acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH (“DiaSys”). Upon completion, DiaSys is now recognized as a majority-owned subsidiary of Mindray.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023.

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity. The test was launched by Personalis in October of this year.

Thermo Fisher Scientific, Pfizer Canada, and Colorectal Cancer Canada have awarded a total of C$300,000 ($221,081) to two Canadian healthcare providers to study the use of next-generation sequencing-based testing in colorectal cancer care.

A total of 13 departments, including the National Health Commission (NHC) and the National Development and Reform Commission (NDRC) have jointly formulated an action-implementation plan for cancer prevention and control from 2023 to 2030.

Today GE HealthCare (Nasdaq: GEHC) announced the release of a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite.

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).

China's in vitro diagnosis began in the 1980s. In the past years, the Chinese IVD industry has been following the trend of national reform and opening up and has made great achievements in the world. At present, China's IVD has developed into a complete industrial chain from reagent instrument system to raw materials and from the domestic market to the global market. Its products have covered all the subdivided fields of the industry and become one of the countries with the most complete product lines of IVD industry in the world.

Revvity said on Monday it has received a CE-IVD mark for a molecular testing platform that can be used to screen newborns for spinal muscular atrophy and severe combined immunodeficiency.

Roche announced on Monday that its hepatitis B immunoassay has received CE marking and is available for use in countries accepting the regulatory designation.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Broncus has entered an equity transfer agreement to acquire a 100% equity interest in Chinese device company Hangzhou Jingliang.

According to the Global Burden of Disease Study 2019, the number of people diagnosed with dementia is expected to almost triple by 2050.

Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund"). Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. ("Sanway Spring") and certain other investors. The JV Agreement was signed on October 27, 2023.

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.